Quantcast
Channel: Market Access
Viewing all 174 articles
Browse latest View live

Oncology Europe

0
0
Event Duration
Event Date: 
Wed, 2013-11-20 - Thu, 2013-11-21
Event Location: 
Berlin
History: 
5th Annual
Number of attendees: 
150
Event Organiser: 
Aidan Brain
Event Organiser E-mail: 
Précis: 
Accelerate market access for oncology drugs through stronger payer relationships

Market Access Canada

0
0
Event Duration
Event Date: 
Mon, 2013-10-28 - Tue, 2013-10-29
Event Location: 
Toronto, Canada
Number of attendees: 
150
Event Organiser: 
Brynn Smith-Raska
Event Organiser E-mail: 
Précis: 
Learn how to traverse this new pan-Canadian landscape to guarantee market access

Challenges in the Shift to Payer Marketing and Engagement

0
0
Précis: 
Pharma companies are moving away from prescriber marketing towards customer-centric discussions with payers and providers. In this article, we outline some of the major obstacles that stand in the way of this adjustment.

The cost of employing a sales force to distribute clinical data, marketing information and drug samples to very large numbers of physicians has become unsustainable. Building and maintaining effective working relationships with physicians has been estimated to cost tens of thousands of dollars per physician in the U.S.(1).

Image: 
Primary Event: 
Premium`: 
No

read more

Free Trade Agreement Could Prioritize Commercial Interests Over Public Services

0
0
Précis: 
The TTIP, currently in negotiations between the EU and the US, may compromise the safety of and restrict access to affordable drugs, and damage effective regulation in expanding fields such as biotechnology, say sixty three signatories of a letter sent to The White House and the European Commission.

The campaigning groups, whose letter was addressed to President Barack Obama, EC President José Manuel Barroso, and European Council President Herman Van Rompuy,fear that the Transatlantic Trade and Investment Partnership (TTIP) may damage public services in favor of commercial interests, by, among other things, introducing investor protection measures which would enable corporations to sue a government that acts in a way that endangers profits.

Image: 
Primary Event: 
Premium`: 
No

read more

FDA Continues To Delay Merck Drug To Reverse Anesthesia

0
0
Précis: 
Merck & Co Inc. announced this week that more time was needed by the US Food and Drug Administration (FDA) to assess its application to sell sugammadex, an injection designed to reverse the effects of muscle relaxants used during surgery.

The announcement reported by Reuters followed a cancelled meeting of outside advisers by the FDA. Merck said the FDA had told them they needed additional time to assess the results of its recently completed inspection of one of the company's clinical trial sites.

Image: 
Primary Event: 
Premium`: 
No

read more

A Payer View On Pricing and Reimbursement in Italy

0
0
Précis: 
Understanding more about what payers want means pharma is better positioned to create value adding propositions. With this in mind eyeforpharma talks with Giuseppe Rosano, Expert Member of AIFA & EMA, about some of the challenges and opportunities that manufacturers are facing in Italy.

Within the European Union the policy for pharmaceuticals focuses on linking a high level of public health with innovation, ultimately aiming to ensure that Europeans continue to benefit from new medicines. This suggests that market access conditions for manufacturers within individual Member States should be relatively smooth.

Image: 
Premium`: 
No

read more

Free Webinar: Create Perfect Value Propositions

US Deals Delay 20 Blockbuster Generics up to Nine Years

0
0
Précis: 
Pay-for-delay deals resulted in US patients paying on average 10 times more than necessary for at least 20 blockbuster medications, according to a new report.

These deals have kept generic versions of patented meds off the market for an average of five years, and in some cases as many as nine years, allowing branded drug companies to rack up $98 billion in sales, says the report from Community Catalyst and the US Public Interest Research Group (USPIRG). Moreover, the findings are described in the report as “just the tip of the iceberg.”

Image: 
Premium`: 
No

read more


Trade Agreement Won’t Affect Public Health According to EC Officials

0
0
Précis: 
Health will not be on the table in the on-going Transatlantic Trade and Investment Partnership according to EU negotiators, alleviating earlier concerns that that the deal could compromise the safety of food and drugs as well as access to affordable medicines.

At a private meeting in Brussels on 16th July, European Commission officials briefed non-governmental organizations and civil society representatives on the outcome of the opening negotiations held in Washington, DC, on 8 July. They assured that the public health sector was not discussed in the first round of talks, but also that there was no plan for it to be included in any following rounds of negotiations, despite earlier claims that the talks will include all subjects.

Image: 
Primary Event: 
Premium`: 
No

read more

The Route to Market Access in Mexico

0
0
Précis: 
How can foreign companies achieve better market penetration in one of Latin America’s largest and most dynamic emerging markets? Ben Steele talks with Rafael Gual, director general of Mexico’s pharmaceutical trade association CANIFARMA, about the regulatory environment.

According to Rafael, the main criterion used by Mexico’s national regulatory agency COFEPRIS to assess new medications is cost-containment. This means that “pharma companies will need to be prepared with pharmacoeconomic studies showing how the drug stands out from those already on the market.”

 

Image: 
Primary Event: 
Premium`: 
No

read more

Exclusive: Richard Bergström Explains Transatlantic Joint Principles for Clinical Data Sharing

0
0
Précis: 
This week the European Federation of Pharmaceutical Industries and Associations (EFPIA) and Pharmaceutical Research and Manufacturers of America (PhRMA) released a joint position paper for responsible clinical trial data sharing to benefit patients.

Speaking exclusively to eyeforpharma, Richard Bergström, EFPIA Director General, explains the intentions of the joint position document, discusses continuing concerns over privacy and his hopes that industry and legislators can collaborate on the best way forward for transparency…

Image: 
Primary Event: 
Premium`: 
No

read more

UPDATED Exclusive: The Devil is in the Details – How The Guardian's Bias Towards One Leaked Memo Proves Greater Transparency is Needed From All

0
0
Précis: 
The ongoing battle for clinical trial transparency took an unexpected turn this past Sunday, 21st July, when the Guardian ran a story featuring details of a leaked memo, apparently containing a plan to conceal “secret documents on drugs trials” from the public and concerned medical practitioners.

On Wednesday, 24thJuly, EFPIA and PhRMA responded to the ongoing argument with a joint set of new principles aimed at addressing these transparency concerns. Speaking exclusively to eyeforpharma, Richard Bergström, EFPIA Director General, explains the intentions of the joint position document and the real story behind that leaked memo….

Image: 
Premium`: 
No

read more

European Commission Launch Inquiry Into Alleged Aid To German Pharma Companies

0
0
Précis: 
The European Commission has opened an in-depth investigation to verify whether a German scheme which is granting companies in financial difficulties exemptions is in line with European Union state aid rules.

The Commission is investigating German law on rebates for pharmaceutical companies facing financial problems. Based on Council Directive 89/105/EEC which allows Member States to impose a price freeze on medicinal products, Germany introduced an obligatory manufacturer's rebate of 16 per cent to be granted by producers of certain prescription medicines to public sickness funds and private health insurers between 1 August 2010 and 31 December 2013.

Image: 
Primary Event: 
Premium`: 
No

read more

252% Increase in M&A Activity Since First Quarter in 2013

0
0
Précis: 
Healthcare M&A activity has increased in the second quarter of 2013, despite this quarter yielding worse results than the same period in 2012, says business intelligence firm.

Through ‘The Health Care M&A report’, Irving Levin Associates demonstrates that the original total spend for health care M&A activity in the second quarter of 2013 was $52.6 billion, an increase of $37.7 billion from the first period of this financial year. When compared with second quarter of 2012, deal value was steady in the same period for this year although its volume increased by 10% since the previous period.  

Image: 
Primary Event: 
Premium`: 
No

read more

Why Pharma Should Think Big And Act Small

0
0
Précis: 
In today’s rapidly changing healthcare landscape, some business leaders believe that pharma needs to be more flexible in order adapt. Lucy Brake talks with AbbVie Australia & New Zealand and A. Menarini Australia Pty Ltd about how leaner, more nimble pharmacos can lead to greater success.

Some companies seem to get too big to be effective, where mergers can often reduce shareholder values as efficiencies tend to disappear, this raises the question: just how big is too big?

Image: 
Premium`: 
No

read more


AstraZeneca Increases Chinese Investment Despite Industry Scrutiny

0
0
Précis: 
AstraZeneca (AZ) is adding to its investment in China, where sales showed a 21 percent increase in the second quarter, all while Chinese government continues its crackdown on corruption in the healthcare industry.

Image: 
Primary Event: 
Premium`: 
No

read more

A Local Flavor will Bring You Sales Success in Brazil

0
0
Précis: 
Lucy Brake talks with Carlos Grzelak Jr, Sales & Access Director at Glenmark Pharmaceuticals Ltd in Brazil about the secrets to running a successful sales and market access strategy in a country that is the second largest only to China among emerging markets.

Image: 
Primary Event: 
Premium`: 
No

read more

Novartis – Owning Responsibility for Payer Relations

0
0
Précis: 
eyeforpharma speaks to Andras Fehervary, Novartis’s Head of Government Affairs and Public Policy on the importance of a consolidated European payer engagement strategy, and how pharma can ensure increasing cost containment works for them.

Image: 
Premium`: 
No

read more

The Formulary – Your Key to Mexican Market Access

0
0
Précis: 
Zuzanna Fimińska interviews Edith Lemus Carmona, Health Economics Manager at Novartis Mexico, about the need for new guidelines on what to include on the mexican national formulary.

“We need to find a way to prioritize by considering what the main public health concerns are, what drugs or treatments will change disease history in terms of mortality and morbidity, and what things as a country we need to search for."

Image: 
Primary Event: 
Premium`: 
No

read more

Transparency Taken Too Far? Interview with Dr. Alexander Natz, Secretary General of EUCOPE

0
0
Précis: 
Dr. Alexander Natz, the Secretary General of European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), discusses the need to protect competitive information in the light of the on-going transparency debate, HTA Assessments and protecting rebates in an age of EU price comparison.

Image: 
Primary Event: 
Premium`: 
No

read more

Viewing all 174 articles
Browse latest View live




Latest Images